|Print This Page Email to a Friend|
Radiation oncologist Elesyia Outlaw, M.D., has joined MCI as director of the Women’s Radiotherapy Program. Outlaw's interests and areas of expertise include women’s cancer -- both breast and gynecologic malignancies. She will also serve as director of the MCI Brachytherapy Program and associate professor of interdisciplinary clinical oncology.
“I am pleased to welcome Dr. Outlaw to MCI as we expand our Radiation Oncology services,” said Dr. Michael A. Finan, MCI director. “Her focus on breast and gynecologic malignancies reinforces MCI’s comprehensive women’s cancer program.”
A native of Kansas City, Missouri, Outlaw is the third radiation oncologist to join the department this year, following Clayton Smith, M.D., Ph.D., and Weisi Yan, M.D., Ph.D.
Outlaw said her goal as an oncologist is to offer patients curative therapy in a manner that protects their quality of life. “Cancer survivorship care is a passion of mine,” she said. “I want to help my patients live their lives to the fullest.”
Prior to her arrival at MCI, Outlaw served as an attending radiation oncologist at Touro Infirmary and Tulane Cancer Center in New Orleans. She earned a medical degree from St. Louis University School of Medicine in 2002. She completed a year of clinical research in breast cancer at MD Anderson Cancer Center in Houston, an internship in the Department of Internal Medicine at Presbyterian Hospital of Dallas and a residency in radiation oncology at Siteman Cancer Center at Washington University in St. Louis.
Outlaw said she enjoys getting to know her patients, their caregivers and friends. “Cancer doesn’t just affect a person from a physical standpoint. It affects every aspect of their lives,” she said. “We have the ability to impact all of those areas.”
Among her honors are Outstanding Biology Graduate at Avila University, the Alpha Sigma Nu Jesuit Honor Society at St. Louis University, the Gordon Research Conference Travel Award and the AACR/ASCO Methods in Clinical Cancer Research.
Outlaw’s previous grant support includes a Clinical Scholar Program award through the National Center for Research Resources (a component of the NIH). She was also awarded a Research Development Fellowship for “DNA Repair Defects as a Therapeutic Strategy,” from the Siteman Cancer Center at Washington University in St. Louis for 2006-07. She has authored seven peer-reviewed publications, and five abstracts.
© 2018 USA Health